Yoshiyasu Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoshiyasu Kato has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
Katsuhiko Uesaka
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Nagaizumi Japan
7 shared publicationsRyo Ashida
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Nagaizumi Japan
6 shared publicationsTeiichi Sugiura
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Nagaizumi Japan
6 shared publicationsKatsuhisa Ohgi
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Nagaizumi Japan
5 shared publicationsHideyuki Dei
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Nagaizumi Japan
4 shared publications- Shimpei Otsuka
Division of Hepato‐Biliary‐Pancreatic Surgery Shizuoka Cancer Center Shizuoka Japan
4 shared publications
Latest Publications
- 17 December 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (4) , 550-561
Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma
Background: The Japan Liver Cancer Association and the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery proposed oncological resectability criteria for hepatocellular carcinoma (HCC), classifying tumors as R, BR1, or BR2. However, serum tumor markers, such as alpha‐fetoprotein (AFP) and des‐gamma‐carboxyprothrombin (DCP), despite their prognostic value, were not incorporated. Methods: We retrospectively analyzed 803 patients undergoing curative liver resection for HCC. Significant tumor marker elevation (TM‐high) was defined as AFP > 500 ng/mL or DCP > 1000 mAU/mL. Overall survival (OS) and relapse‐free survival (RFS) were compared according to resectability status and tumor marker levels. Results: TM‐high status was observed in 171 patients with R (32.3%), 75 patients with BR1 (27.5%), and 46 patients with BR2 (70.1%). In the R group, TM‐high patients had significantly worse outcomes than non‐TM‐high patients (median survival time [MST], RFS: 26.9 vs. 55.9 months, and p < 0.001; OS: 120.7 vs. 160.8 months and p = 0.008). No significant difference in the OS was observed between R/TM‐high and BR1/non–TM‐high patients (120.7 vs. 103.1 months and p = 0.159) or BR1/TM‐high and BR2/non–TM‐high patients (58.7 vs. 58.5 months and p = 0.657). Multivariate analyses confirmed that a TM‐high status was an independent predictor for both the RFS (HR 1.36 and p < 0.003) and OS (HR 1.50 and p < 0.001). Conclusion: AFP and DCP provide independent prognostic information beyond the oncological resectability criteria. Incorporating tumor markers may refine risk stratification and optimize multidisciplinary treatment strategies for HCC.
- 17 December 2025
- Published by Wiley in Hepatology Research
- Vol. 56 (4) , 550-561
Significance of Evaluating Tumor Markers in the Oncological Criteria for Resectability in Hepatocellular Carcinoma
Background: The Japan Liver Cancer Association and the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery proposed oncological resectability criteria for hepatocellular carcinoma (HCC), classifying tumors as R, BR1, or BR2. However, serum tumor markers, such as alpha‐fetoprotein (AFP) and des‐gamma‐carboxyprothrombin (DCP), despite their prognostic value, were not incorporated. Methods: We retrospectively analyzed 803 patients undergoing curative liver resection for HCC. Significant tumor marker elevation (TM‐high) was defined as AFP > 500 ng/mL or DCP > 1000 mAU/mL. Overall survival (OS) and relapse‐free survival (RFS) were compared according to resectability status and tumor marker levels. Results: TM‐high status was observed in 171 patients with R (32.3%), 75 patients with BR1 (27.5%), and 46 patients with BR2 (70.1%). In the R group, TM‐high patients had significantly worse outcomes than non‐TM‐high patients (median survival time [MST], RFS: 26.9 vs. 55.9 months, and p < 0.001; OS: 120.7 vs. 160.8 months and p = 0.008). No significant difference in the OS was observed between R/TM‐high and BR1/non–TM‐high patients (120.7 vs. 103.1 months and p = 0.159) or BR1/TM‐high and BR2/non–TM‐high patients (58.7 vs. 58.5 months and p = 0.657). Multivariate analyses confirmed that a TM‐high status was an independent predictor for both the RFS (HR 1.36 and p < 0.003) and OS (HR 1.50 and p < 0.001). Conclusion: AFP and DCP provide independent prognostic information beyond the oncological resectability criteria. Incorporating tumor markers may refine risk stratification and optimize multidisciplinary treatment strategies for HCC.
- Open Access
- 6 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Reappraising the prognostic role of liver resection as part of extended cholecystectomy for T2 gallbladder cancer
- 6 December 2025
- Published by Elsevier in Clinical Surgical Oncology
- Vol. 4 (4)
Open AccessReappraising the prognostic role of liver resection as part of extended cholecystectomy for T2 gallbladder cancer
- 2 September 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (11) , 847-855
Shorter Pancreatic Division‐To‐Anastomosis Time Reduces Drain Amylase Levels After Pancreatoduodenectomy for Nonpancreatic Cancer
Background: Despite advances in surgical techniques, postoperative pancreatic fistula (POPF) remains a major concern after pancreatoduodenectomy (PD). Although various risk factors have been identified, most are patient‐specific and nonmodifiable. This study investigated whether the time from pancreatic division to anastomosis (division‐to‐anastomosis time, DAT) influences postoperative outcomes. Methods: We retrospectively analyzed 182 patients who underwent PD for nonpancreatic cancer between 2017 and 2022. The relationship between DAT and drain amylase (D‐amy) levels on postoperative day 3 was evaluated. We also investigated the association between DAT and POPF development. Multiple regression analyses were performed to adjust for potential confounding factors. Results: Median patient age was 72 years, and 64.8% were male. Primary diagnoses included distal bile duct (35.7%), ampullary (24.7%), and duodenal (7.7%) cancers. Longer DAT was independently associated with increased D‐amy levels (regression coefficient 0.16, 95% confidence interval: 0.0–0.29), with each hourly increase in DAT corresponding to a 1.45‐fold increase. Grade B POPF occurred in 48% of cases. Multivariate analysis identified prolonged DAT and higher BMI as independent POPF risk factors. Conclusions: Prolonged DAT during PD was associated with increased D‐amy levels and POPF incidence. As a modifiable surgical factor, DAT represents a potential target for technical refinement to improve postoperative outcomes.
- 2 September 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (11) , 847-855
Shorter Pancreatic Division‐To‐Anastomosis Time Reduces Drain Amylase Levels After Pancreatoduodenectomy for Nonpancreatic Cancer
Background: Despite advances in surgical techniques, postoperative pancreatic fistula (POPF) remains a major concern after pancreatoduodenectomy (PD). Although various risk factors have been identified, most are patient‐specific and nonmodifiable. This study investigated whether the time from pancreatic division to anastomosis (division‐to‐anastomosis time, DAT) influences postoperative outcomes. Methods: We retrospectively analyzed 182 patients who underwent PD for nonpancreatic cancer between 2017 and 2022. The relationship between DAT and drain amylase (D‐amy) levels on postoperative day 3 was evaluated. We also investigated the association between DAT and POPF development. Multiple regression analyses were performed to adjust for potential confounding factors. Results: Median patient age was 72 years, and 64.8% were male. Primary diagnoses included distal bile duct (35.7%), ampullary (24.7%), and duodenal (7.7%) cancers. Longer DAT was independently associated with increased D‐amy levels (regression coefficient 0.16, 95% confidence interval: 0.0–0.29), with each hourly increase in DAT corresponding to a 1.45‐fold increase. Grade B POPF occurred in 48% of cases. Multivariate analysis identified prolonged DAT and higher BMI as independent POPF risk factors. Conclusions: Prolonged DAT during PD was associated with increased D‐amy levels and POPF incidence. As a modifiable surgical factor, DAT represents a potential target for technical refinement to improve postoperative outcomes.
- 19 March 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (5)
Rectus abdominis muscle wrap for effective control of hepatic artery bleeding
- 19 March 2025
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 32 (5)
Rectus abdominis muscle wrap for effective control of hepatic artery bleeding
- 3 March 2025
- Published by Wolters Kluwer Health in Pancreas
- Vol. 54 (7) , e630-e636
Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases
Background: Neoadjuvant therapy (NAT) followed by surgery is becoming a standard treatment even for resectable pancreatic cancer (RPC). However, it is unclear whether NAT is necessary for all RPC cases. Methods: A total of 296 patients diagnosed with RPC and under 80 years old were retrospectively analyzed, focusing on tumor markers (TMs). The cutoff value of TM was decided based on the classification by the International Association of Pancreatology. Results: Among 80 cases who underwent NAT, 72 cases accomplished surgical resection. Upfront surgery (UpS) was planned in 216 cases, and surgical resection was accomplished in 199 cases. Resection rate showed no difference between the two groups (P = 0.638). Although NAT group showed a favorable trend in overall survival (OS) compared with the UpS group, the difference was not significant (P = 0.143). carbohydrate antigen 19-9 >500 U/mL and/or duke pancreatic monoclonal antigen type 2 >700 U/mL was defined as high TM. When comparing in TM-high group (n = 83), patients with NAT showed significantly better OS than those without NAT (P = 0.024). In TM-low group (n = 213), the OS curves completely overlapped with no difference (P = 0.902). A multivariate analysis demonstrated that undergoing NAT was the sole independent prognostic factor in the TM-high group (hazard ratio: 0.48, P = 0.044) while undergoing NAT was not a prognostic factor in the TM-low group. Conclusion: The efficacy of NAT for RPC might be limited to the subset of patients with high TM.
- 3 March 2025
- Published by Wolters Kluwer Health in Pancreas
- Vol. 54 (7) , e630-e636
Efficacy of Neoadjuvant Therapy for Resectable Pancreatic Cancer Might be Limited to Biologically Borderline Resectable Cases
Background: Neoadjuvant therapy (NAT) followed by surgery is becoming a standard treatment even for resectable pancreatic cancer (RPC). However, it is unclear whether NAT is necessary for all RPC cases. Methods: A total of 296 patients diagnosed with RPC and under 80 years old were retrospectively analyzed, focusing on tumor markers (TMs). The cutoff value of TM was decided based on the classification by the International Association of Pancreatology. Results: Among 80 cases who underwent NAT, 72 cases accomplished surgical resection. Upfront surgery (UpS) was planned in 216 cases, and surgical resection was accomplished in 199 cases. Resection rate showed no difference between the two groups (P = 0.638). Although NAT group showed a favorable trend in overall survival (OS) compared with the UpS group, the difference was not significant (P = 0.143). carbohydrate antigen 19-9 >500 U/mL and/or duke pancreatic monoclonal antigen type 2 >700 U/mL was defined as high TM. When comparing in TM-high group (n = 83), patients with NAT showed significantly better OS than those without NAT (P = 0.024). In TM-low group (n = 213), the OS curves completely overlapped with no difference (P = 0.902). A multivariate analysis demonstrated that undergoing NAT was the sole independent prognostic factor in the TM-high group (hazard ratio: 0.48, P = 0.044) while undergoing NAT was not a prognostic factor in the TM-low group. Conclusion: The efficacy of NAT for RPC might be limited to the subset of patients with high TM.
- 30 June 2024
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (8) , 559-568
Subdivision of pT1N0 (American Joint Committee on Cancer 8th edition) distal cholangiocarcinoma for adjuvant chemotherapy consideration
Background: The adjuvant S‐1 trial affirmed adjuvant chemotherapy for biliary tract cancer but excluded pT1N0 distal cholangiocarcinoma (DCC) according to the seventh edition of the American Joint Committee on Cancer (AJCC) classification. The introduction of tumor depth of invasion (DOI) for T‐classification in the eighth edition complicates identifying DCC patients less likely to benefit from adjuvant chemotherapy.Methods: Our cohort consisted of 185 patients with DCC who underwent pancreaticoduodenectomy between 2002 and 2019. We compared clinicopathological factors and survival outcomes between pT1N0 patients in the seventh edition and those in the eighth edition. New DOI cutoffs for subdividing pT1N0 (8th edition) patients were evaluated to identify patients less likely to benefit from adjuvant chemotherapy.Results: Transitioning to the eighth edition increased in pT1N0 cases from eight to 46. The 5‐year cumulative recurrence rates of them were 14.3% for the seventh edition and 28.3% for the eighth edition. We proposed a DOI cutoff of <2 mm, at which the 5‐year cumulative recurrence rate was 11.5%.Conclusion: The eighth AJCC classification revealed that a significant proportion of pT1N0 DCC patients were at risk for recurrence. A DOI cutoff of <2 mm may be considered to potentially improve patient selection for adjuvant chemotherapy.
- 30 June 2024
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 31 (8) , 559-568
Subdivision of pT1N0 (American Joint Committee on Cancer 8th edition) distal cholangiocarcinoma for adjuvant chemotherapy consideration
Background: The adjuvant S‐1 trial affirmed adjuvant chemotherapy for biliary tract cancer but excluded pT1N0 distal cholangiocarcinoma (DCC) according to the seventh edition of the American Joint Committee on Cancer (AJCC) classification. The introduction of tumor depth of invasion (DOI) for T‐classification in the eighth edition complicates identifying DCC patients less likely to benefit from adjuvant chemotherapy.Methods: Our cohort consisted of 185 patients with DCC who underwent pancreaticoduodenectomy between 2002 and 2019. We compared clinicopathological factors and survival outcomes between pT1N0 patients in the seventh edition and those in the eighth edition. New DOI cutoffs for subdividing pT1N0 (8th edition) patients were evaluated to identify patients less likely to benefit from adjuvant chemotherapy.Results: Transitioning to the eighth edition increased in pT1N0 cases from eight to 46. The 5‐year cumulative recurrence rates of them were 14.3% for the seventh edition and 28.3% for the eighth edition. We proposed a DOI cutoff of <2 mm, at which the 5‐year cumulative recurrence rate was 11.5%.Conclusion: The eighth AJCC classification revealed that a significant proportion of pT1N0 DCC patients were at risk for recurrence. A DOI cutoff of <2 mm may be considered to potentially improve patient selection for adjuvant chemotherapy.
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S8
Randomized controlled trial of artificial intelligence diagnostic system in clinical practice to detect esophageal squamous cell carcinoma
Aims We have developed the artificial intelligence (AI) diagnostic system for the detection of superficial esophageal squamous cell carcinoma (ESCC) applied deep learning system. The aim of this study was to reveal the effect of AI diagnostic system on the improvement of ESCC detection in clinical trial. Methods This study was a prospective, single-center, exploratory randomized controlled trial. From October 2020 to November 2021, 325 patients undergoing screening or surveillance esophagogastroduodenoscopy with primary head and neck cancer and/or ESCC were enrolled. All participants were randomly assigned to either AI group (n=155) or control group (n=170). In both groups, expert and non-expert endoscopists screened the esophagus with WLI followed by NBI with or without AI assistance. Then, after iodine chromoendoscopy of the esophagus, we took biopsies from suspicious ESCCs detected by any of the modalities. The primary endpoint was the additional effect on the detection rate of ESCC with AI diagnostic system in non-experts. Results Among 325 patients, 41 lesions of ESCC (21 in AI group, 20 in control group) were diagnosed. Non-experts could detect 44% of ESCCs (7/16) in AI group, and 45% (5/11) in control group. Experts could detect 87% of ESCCs (4/5) in AI group, and 57% (5/9) in control group. No significant differences were observed in terms of detection sensitivity in non-experts between the two groups (p=0.94), as well as in all endoscopists (53% vs 50%, p=0.84). Conclusions AI diagnostic system could not improve the detection rate of ESCC in this clinical trial. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S8
Randomized controlled trial of artificial intelligence diagnostic system in clinical practice to detect esophageal squamous cell carcinoma
Aims We have developed the artificial intelligence (AI) diagnostic system for the detection of superficial esophageal squamous cell carcinoma (ESCC) applied deep learning system. The aim of this study was to reveal the effect of AI diagnostic system on the improvement of ESCC detection in clinical trial. Methods This study was a prospective, single-center, exploratory randomized controlled trial. From October 2020 to November 2021, 325 patients undergoing screening or surveillance esophagogastroduodenoscopy with primary head and neck cancer and/or ESCC were enrolled. All participants were randomly assigned to either AI group (n=155) or control group (n=170). In both groups, expert and non-expert endoscopists screened the esophagus with WLI followed by NBI with or without AI assistance. Then, after iodine chromoendoscopy of the esophagus, we took biopsies from suspicious ESCCs detected by any of the modalities. The primary endpoint was the additional effect on the detection rate of ESCC with AI diagnostic system in non-experts. Results Among 325 patients, 41 lesions of ESCC (21 in AI group, 20 in control group) were diagnosed. Non-experts could detect 44% of ESCCs (7/16) in AI group, and 45% (5/11) in control group. Experts could detect 87% of ESCCs (4/5) in AI group, and 57% (5/9) in control group. No significant differences were observed in terms of detection sensitivity in non-experts between the two groups (p=0.94), as well as in all endoscopists (53% vs 50%, p=0.84). Conclusions AI diagnostic system could not improve the detection rate of ESCC in this clinical trial. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 August 2018
- Published by Wolters Kluwer Health in Pancreas
- Vol. 47 (7) , 823-829
Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma
Objectives: The controlling nutritional status (CONUT) score is a useful tool to evaluate immune-nutritional status. This study aimed to investigate the impact of the CONUT score on short- and long-term outcomes after curative resection of pancreatic ductal adenocarcinoma (PDAC).Methods: Consecutive 344 PDAC patients receiving pancreatectomy without neoadjuvant therapy were examined retrospectively. After the best predictive value of the CONUT score for survival was identified, association between the CONUT score and long-term outcomes was evaluated using log-rank tests and a Cox regression model. Then correlations between the CONUT score and postoperative complications were analyzed.Results: The optimal cutoff value of the CONUT score was 4. The high CONUT score group showed significantly lower overall survival than the low CONUT score group (P= 0.002). In contrast, no significant difference in recurrence-free survival was found (P= 0.43). A multivariate analysis demonstrated that high CONUT score had an independent association with overall survival (hazard ratio, 1.64;P= 0.003). The CONUT score showed no association with postoperative pancreatic fistula, Clavien-Dindo grade, or postoperative hospital stay.Conclusion: The CONUT score had an independent association with survival in patients with PDAC after pancreatectomy and was not associated with recurrence or postoperative complications.
- 1 August 2018
- Published by Wolters Kluwer Health in Pancreas
- Vol. 47 (7) , 823-829
Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma
Objectives: The controlling nutritional status (CONUT) score is a useful tool to evaluate immune-nutritional status. This study aimed to investigate the impact of the CONUT score on short- and long-term outcomes after curative resection of pancreatic ductal adenocarcinoma (PDAC).Methods: Consecutive 344 PDAC patients receiving pancreatectomy without neoadjuvant therapy were examined retrospectively. After the best predictive value of the CONUT score for survival was identified, association between the CONUT score and long-term outcomes was evaluated using log-rank tests and a Cox regression model. Then correlations between the CONUT score and postoperative complications were analyzed.Results: The optimal cutoff value of the CONUT score was 4. The high CONUT score group showed significantly lower overall survival than the low CONUT score group (P= 0.002). In contrast, no significant difference in recurrence-free survival was found (P= 0.43). A multivariate analysis demonstrated that high CONUT score had an independent association with overall survival (hazard ratio, 1.64;P= 0.003). The CONUT score showed no association with postoperative pancreatic fistula, Clavien-Dindo grade, or postoperative hospital stay.Conclusion: The CONUT score had an independent association with survival in patients with PDAC after pancreatectomy and was not associated with recurrence or postoperative complications.